Journal Mobile Options
Table of Contents
Vol. 97, No. 3, 2002
Issue release date: June 2002
Cardiology 2002;97:115–121
(DOI:10.1159/000063326)

Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?

Muscari A. · Puddu G.M. · Puddu P.
Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Most of the currently available statins and fibric acid derivatives have been implicated in causing complications either in monotherapy or in combination therapy. Adverse events occur more often with the statins that are metabolized via the CYP enzyme system and its 3A4, 2C9 or 2C19 paths. All compounds interfering with the same cytochrome system may either impair or enhance the elimination of statins. Other factors predisposing to adverse effects are age, female sex, renal insufficiency, electrolyte disturbances, infections and trauma. Complications chiefly concern the hepatic function, skeletal muscles and peripheral nerves. The major adverse effect is myopathy, up to rhabdomyolysis with ensuing acute renal insufficiency. Fibrates bind to peroxisome proliferator-activated nuclear receptors α, with subsequent stimulation of fatty acid oxidation and reduction in the rate of hepatic lipid generation. Fibrates are associated with a number of adverse effects, including liver enzyme elevations, gastrointestinal side effects and rhabdomyolysis. The combination of statins with fibrates may cause serious complications and should be avoided when possible. In order to prevent or minimize adverse clinical outcomes, patients should be closely monitored and informed of the most common symptoms.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Blumenthal RS: Statins: Effective antiatherosclerotic therapy. Am Heart J 2000;139:577–583.
  2. Shepherd J: The statin era: In search of the ideal lipid regulating agent. Heart 2001;85:259–264.
  3. Moghadasian MH: Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999;65:1329–1337.
  4. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
  5. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxymethylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B–32B.
  6. Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, Mabuchi H: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol 2000;85:178–183.
  7. Beaird SL: HMG-CoA reductase inhibitors: Assessing differences in drug inter safety profiles. J Am Pharm Assoc 2000;40:637–644.
  8. Wood AJ: Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
  9. Ucar M, Mjorndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441–457.
  10. Maron DJ, Fazio S, Linton MRF: Current perspectives on statins. Circulation 2000;101:207–213.
  11. Grundy SM: Consensus statement: Role of therapy with ‘statins’ in patients with hypertriglyceridemia. Am J Cardiol 1998;81(suppl 4A):1B–6B.
  12. Perault MC, Ladouch-Bures L, Dejean C, Delaunay C, Pouget Abadie JF, Vandel B: Rhabdomyolysis related to ingestion of pravastatin (Vasten). Therapie 1993;48:487.
  13. Haria M, McTavish D: Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drug 1997;53:299–336.
  14. Berg A, Halle M, Baumstark M, Keul J, Northogg H: Spontaneously low LDL-cholesterol and reaction to exercise-induced stress. Lancet 1996;347:405.
  15. De Pinieux G, Chariot P, Ammi-Said M, Louran F, Lejonc JL, Astier A, Jacotot B, Gherardi R: Lipid-lowering drugs and mitochondrial function: Effects of HMG-reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333–337.
  16. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, Osame M: Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological electrophysiological and biochemical study. Toxicol Appl Pharmacol 1998;152:99–106.
  17. Sinzinger H, Lupattelli G, Chehne F: Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 2000;153:255–256.
  18. Sinzinger H, Lupattelli G, Chehne F, Oguogho A, Furberg CD: Isoprostane 8-epi-PGF2 is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 2001;26:303–310.
  19. Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, Laico M, Camerino DL: Potential risk of myopathy by HMG-CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Phamacol Exp Ther 1995;275:1490–1496.
  20. Sinzinger H, Schmid P, O’Grady J: Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 1999;143:459–460.
  21. Gemici G, Toprak A, Oktay A: Rhabdomyolysis due to cerivastatin monotherapy. Am J Med 2001;110:742.
  22. Rodriguez ML, Mora C, Navarro JF: Cerivastatin-induced rhabdomyolysis. Ann Intern Med 2000;132:598.
  23. Garcia-Valdecasas-Campelo E, Gonzales-Reimers E, Lopez-Lirola A, Rodriguez-Rodriguez E, Santolaria-Fernandez F: Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001;161:893.
  24. Martinez-Garcia FA, Martin-Fernandez J, Molto JM, Villaverde R, Morales A, Barreiro A: Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Rev Neurol 1997;25:869–871.
  25. Tobert JA: Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J–34J.
  26. Tobert JA: Lovastatin and myopathy. Am J Med 1994;96:300–301.
  27. Chu PH, Chen WJ, Chiang CW, Lee YS: Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. Jpn Heart J 1997;38:541–545.
  28. Fernandez Zatarain G, Navarro V, Garcia H, Villatoro J, Calvo C: Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron 1994;66:483–484.
  29. FDA Talk Paper, August 8, 2001.
  30. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL: Rhabdomyolysis with simvastatin use. Nephron 1991;57:365–366.
  31. Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A: Rhabdomyolysis due to simvastatin. A propos of a case with review of literature. Rev Rhum Mal Osteoartic 1992;59:281–283.
  32. Wicher-Muniak E, Zmudka K, Dabros W, Dudek D, Stachura J: Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects. Pol J Pathol 1997;48:69–74.
  33. Al Shohaib S: Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am J Nephrol 2000;20:212–213.
  34. Schalke BB, Schmidt B, Toyka K, Hartung HP: Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;327:649–650.
  35. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Linden T, Miettinen T, Odman B, Olofsson S-O, Saarinen I, Sipila R, Sjostrom P, Kron B, Vanhanen H, Wright I: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13–20.
  36. Peters TK: Safety profile of fluvastatin. Br J Clin Pract 1996;77A:20–23.
  37. Liebhaber MI, Wright RS, Gelberg HJ, Dyer Z, Kupperman JL: Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: A report of ten cases. Chest 1999;115:886–889.
  38. Jacobs MB: HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 1994;120:970.
  39. Ahmad S: Lovastatin and peripheral neuropathy. Am Heart J 1995;130:1321.
  40. Phan T, McLeod JG, Pollard IJ, Peiris O, Rohan A, Halpern J-P: Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58:625–628.
  41. Jeppesen U, Gaist D, Smith S, Sindrup SH: Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999;54:835–838.
  42. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH: Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001:56:931–933.
  43. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D: Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 1999;159:1793–1802.
  44. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55–60.
  45. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH: Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials. BMJ 2001;322:11–15.
  46. Piepho RW: The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein in cholesterol. Am J Cardiol 2000;86:35L–40L.
  47. Neve BP, Fruchart JC, Staels B: Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60:1245–1250.
  48. Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141–148.
  49. Latruffe N, Malki MC, Nicolas-Frances V, Clemencet MC, Jannin B, Berlot JP: Regulation of the peroxisomal β-oxidation-dependent pathway by peroxisome proliferator-activated receptor α and kinase. Biochem Pharmacol 2000;60:1027–1032.
  50. Martin G, Duez H, Planquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001;107:1423–1432.
  51. Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83–92.
  52. Bhatnagar D: Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 1998;79:205–230.
  53. Perault MC, Fievre JL, Deyean C, Martin A, Vandel B: Cytolytic hepatic damage caused by ciprofibrate. Gastroenterol Clin Biol 1992;16:609.
  54. Delangre T, Vernier L, Moore N, Mihout B: Acute rhabdomyolysis during treatment with ciprofibrate. Presse Méd 1990;19:1811–1812.
  55. Giraud O, Chanu B, Farge D, Parrot F, Brestescher C, Rouffy J: Acute rhabdomyolysis associated with digestive disorders during an overdose of ciprofibrate. Gastroenterol Clin Biol 1995;19:231–232.
  56. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873–1874.
  57. Clouatre Y, Leblanc M, Ouimet D, Pichette V: Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 1999;14:1047–1048.
  58. Terrovitou CT, Milionis HJ, Elisaf MS: Acute rhabdomyolysis after bezafibrate re-exposure. Nephron 1998;78:336–337.
  59. Gas JM, Prados MC, Perdiguero M, Rivera F: Rhabdomyolysis due to bezafibrate: A new case. Med Clin 1992;98:156–157.
  60. Smals AG, Beex LV, Kloppenborg PW: Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy. N Engl J Med 1977;296:942.
  61. Schneider S, Heudier P, Taillan B, Chichmanian RM, Dujardin P: Muscular toxicity from clofibrate treatment in hypopituitarism: Role of SIADH. Rev Méd Interne 1992;13:398–399.
  62. Heidemann H, Bock KD: Rhabdomyolysis with acute renal failure due to bezafibrate. Klin Wochenschr 1981;59:413–414.
  63. Lipkin GW, Tomson CR: Severe reversible renal failure with bezafibrate. Lancet 1993;341:371.
  64. Gorriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalan C, Pallardo LM: Rhabdomyolysis and acute renal failure associated with gemfibrozil. Nephron 1996;74:437–438.
  65. Venzano C, Cordi GC, Corsi L, Dapelo M, De Micheli A, Grimaldi GP: A case of acute rhabdomyolysis and acute renal insufficiency caused by the simultaneous use of furosemide and bezafibrate. Minerva Med 1990;81:909–911.
  66. Ramachandran S, Giles PD, Hartland A: Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. BMJ 1997;14:1593.
  67. Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998;82(12A):82U–84U.
  68. Mogyorosi A, Bradley B, Showalter A, Schubert ML: Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999;246:599–602.
  69. Lee AJ, Maddix DS: Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26–31.
  70. Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka E: Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000;109:78.
  71. Maltz HC, Balog DL, Cheigh JS: Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999;33:1176–1179.
  72. Shek A Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908–917.
  73. Marais G, Larson K: Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990;112:228–230.
  74. Pogson WG, Kindred LH, Carper BG: Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999;83:1146.
  75. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S: A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. A case report. Angiology 2000;51:695–697.
  76. Tomlinson B, Lan IW: Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable? Am J Med 2001;110:669–670.
  77. Alexandridis G, Pappas GA, Elisaf MS: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 2000;109:261–262.
  78. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD: Rhabdomyolysis in a patient receiving the combination of cerivastatin-gemfibrozil. Am J Health Syst Pharm 2000;57:461–464.
  79. Bruno-Joyce J, Dugas JM, MacCausland OE: Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 2001;35:1016–1019.
  80. Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z: Influenza vaccine – A possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant 2000;15:740–741.
  81. Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA: Concomitant use of cytochrome P405 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811–815.
  82. Van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ: Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996;240:403–404.
  83. Kayikcioglu M, Ozerkan F, Soydan I: Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135–1137.
  84. Rosenson RS: Gemfibrozil-lovastatin-associated myalgia. Am J Cardiol 1993;71:497.
  85. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71–75.
  86. Knoll RW, Ciafone R, Galen M: Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibrozil. Conn Med 1993;57:593–594.
  87. Abdul-Ghaffar NU, el-Sonbaty MR: Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozol therapy. J Clin Gastroenterol 1995;21:340–341.
  88. Duell PB, Connor WE, Illingworth DR: Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998;81:368–369.
  89. Puddu P, Puddu GM, Muscari A: HMG-CoA reductase inhibitors: Is the endothelium the main target? Cardiology 2001;95:9–13.
  90. Puddu P, Puddu GM, Muscari A: Current thinking in statin therapy. Acta Cardiol 2001;56:225–231.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50